Pharma's Top 10 Blockbuster Drugs

Welcome to FiercePharma's look at the bestselling drugs of 2009. With the help of EvaluatePharma and PriceWaterhouse Coopers, we've identified a mix of old standbys and disease-altering biologics that make up this year's top 10 list. Some brands--such as Lipitor, Plavix, Advair--will be facing serious generic competition in the near future, while the harder-to-copy biologics are, for the time being, protected from copycats. In the coming years, EvaluatePharma predicts the top 10 list will be dominated by biologics as more small molecules go off-patent. Two top-selling mainstays, AstraZeneca's Nexium and Amgen's Epogen/Procrit, are absent from this year's list; Humira and Seroquel have taken their place. Click here to begin the slideshow ->

Suggested Articles

BMS' Opdivo-Yervoy combo is playing in an increasingly crowded space. But the company is leaning on new long-term data to set its regimen apart.

GSK and Alcon have pulled off prescription-to-OTC switches in hopes of giving aging brands Voltaren and Pataday a boost.

Sanofi didn't hesitate to enter Zika vaccine R&D, and despite the associated scandal, the company is again jumping into emerging disease vaccine R…